ClinicalTrials.gg
CompletedNCT07246252Updated Nov 24, 2025

Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects

A Phase 1 interventional study of Process-Changed CMAB007 and Xolair (omalizumab) in Healthy Volunteers (HV), sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2024, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, safety and immunogenicity of two formulations of Omalizumab (Process-Changed CMAB007 and Xolair) in healthy subjects.

Read the detailed description

This is a randomized, double-blind, parallel-controlled, single-dose phase I clinical study in healthy Chinese male subjects. A total of 114 subjects were planned to be enrolled and randomly assigned to the test group or the control group in a 1:1 ratio. Subjects in both groups received a single subcutaneous injection of Process-Changed CMAB007 or Xolair(Omalizumab) 150 mg, respectively. Subjects in both groups were observed for 106 days after administration to evaluate similarities in PK, safety, and immunogenicity.

02

Conditions studied

  • Healthy Volunteers (HV)
03

In context

Lead sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd is the lead sponsor of 18 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers, age ranged 18 to 45 years (both inclusive) when sign the form.
  2. Subjects with body weight of ≥50 kg and ≤ 75 kg and ≥20.0 and ≤ 26.0 kg/m2 (both inclusive).
  3. Subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; moreover, subjects can communicate well with researchers and complete the research according to the regulations.
  4. Subjects must be informed consent of the study and voluntarily sign informed consent form (name and time) prior to the study.

Exclusion criteria

Exclusion Criteria:

  1. After medical examination (vital signs, physical examination, , positive chest X-radiography, abdominal B-ultrasound, and various laboratory examinations including blood routine, urine routine, blood biochemistry and total IgE, etc.), any examination item was judged abnormal by the investigator and had clinical significance.
  2. Subjects with a history of drug or food allergies, a history of specific allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), allergic rhinitis, or a known allergy to any component of the drug or latex (the syringe needle cover contains latex) as determined by the investigator..
  3. Those who have a history of serious diseases including but not limited to cardiovascular system, respiratory system, digestive system, urogenital system, endocrine system, immune system, mental or nervous system (eg, epilepsy, etc), or currently have any of the above diseases or active infected diseases, or any other disease or medical condition that may interfere with the results of the trial, such as hereditary bleeding tendency, coagulation disorders or history of blood clots or bleeding.
  4. History of malignant neoplasms within the last 5 years (other than completely resected basal cell or squamous cell carcinoma of the skin in situ).
  5. Any one of surface antigen, antibody, antibody and treponema pallidum antibody is positive.
  6. Anti-nuclear antibody is positive.
  7. Fecal parasite test is positive.
  8. Those who smoke more than 10 cigarettes per day on average in the 6 months before screening.
  9. Alcoholics or regular drinkers within 3 months before the test, i.e. those who drink more than 14 unites of alcohol per week (14 bottles of 360 ml beer or 45 ml spirits with 40% alcohol or 150 ml wine), or whose alcohol breath test is positive.
  10. Drug abusers, or use of soft drugs within 3 months prior to screening or hard drugs within 1 year prior the trial, or excessive daily consumption of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250mL) in the 3 months prior to screening, or positive urine drug screening.
  11. Surgery within 4 weeks prior to screening; Or plan to have surgery during the study period.
  12. Use of any prescription drug, over-the-counter drug or health product or vaccine within 4 weeks prior to screening, or who plan to receive during the study period, or prior use of drug within 5 half-lives, whichever is longer.
  13. Subjects who have donated blood (including whole blood or component blood) or experienced blood loss of more than 400 mL within 3 months prior to screening, or have received a blood transfusion; or who have donated blood (including component blood) or experienced blood loss of more than 200 mL within 1 month prior to screening; or who plan to donate blood during the study period..
  14. Those who have been enrolled in other clinical studies or less than 3 months since the end of the most recent clinical study.
  15. Subjects and their partners were not willing to use medically approved methods within 6 months of study administration, or partners plan to become pregnant, or subjects plan to donate sperm.
  16. Use of anti-IgE mab within 12 months, or any biological agent within 3 months prior to screening.
  17. The investigator judges the subject inappropriate to be included in this study or other reasons not eligible to complete the study.
  18. Employees or related personnel of the research unit, sponsor or contract research organization.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Process-Changed CMAB007

    150 mg Subcutaneous injection

    Biological: Process-Changed CMAB007

  • Active comparator
    Xolair

    150 mg Subcutaneous injection

    Biological: Xolair (omalizumab)

Interventions

  • BiologicalProcess-Changed CMAB007

    for subcutaneous injection only

  • for subcutaneous injection only

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time

    Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single injection of Omalizumab

    Time frame: up to 2520 hours

  2. Maximum Concentration of Omalizumab

    Maximum Concentration After the Single Injection of Omalizumab

    Time frame: up to 2520 hours

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2520 Hours

    Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2520 Hours After the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  2. Time to Maximum Concentration of Omalizumab

    Time to Maximum Concentration of Omalizumab after the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  3. Half time

    Half-time after the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  4. Terminal elimination rate constant (λz)

    Terminal elimination rate constant (λz) after the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  5. Apparent total body clearance (CL/F)

    Apparent total body clearance (CL/F) after the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  6. Apparent total distribution (Vd/F)

    Apparent total distribution (Vd/F) after the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  7. anti-drug antibodies (ADA)

    ADA Positive Rate after the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  8. Neutralization antibodies (Nab)

    Neutralizing Antibody Positive Rate after the Single Injection of Omalizumab

    Time frame: up to 2520 hours

  9. Percentage and Severity of Participants with Adverse Events

    Total Frequency and Severity of Adverse Events/Serious Adverse Events Within the Whole Time of the Study

    Time frame: up to 2520 hours

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital, Shanghai
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Sep 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Mar 28, 2024
Primary completionActual
Sep 30, 2024
CompletionActual
Dec 2, 2024
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07246252
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Mar 28, 2024
Primary completion
Sep 30, 2024
Completion
Dec 2, 2024
Last update
Nov 24, 2025

Study contacts

Jingying Jia, Ph.D
principal investigator · Shanghai Xuhui Central Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion